Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acclaim-1: Quaratusugene Ozeplasmid + Osimertinib in Advanced EGFR-Mutant NSCLC
NCT04486833Phase 2Recruiting
- Sponsor
- Genprex, Inc.
- Start
- Sep 2021
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of quaratusugene ozeplasmid in non-small cell lung cancer (NSCLC), sponsored by Genprex, Inc.. Started Sep 2021; status: recruiting.
02
Drugs
quaratusugene ozeplasmid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04486833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486833.